The bill amends section 461.007 of the Florida Statutes to require that only certain podiatric physicians, specifically those registered with the United States Drug Enforcement Administration and authorized to prescribe controlled substances, complete a minimum of 40 hours of continuing education every two years, including at least 2 hours related to safe prescribing practices. Additionally, the bill creates a new section, 461.011, which establishes guidelines for podiatric physicians performing procedures using cellular or tissue-based products that are not FDA-approved. This section includes legislative findings, definitions, and specific requirements for the use of such products, including obtaining patient consent and providing clear notices in advertisements.

Under the new provisions, podiatric physicians are authorized to use cellular or tissue-based products for specific treatments related to connective tissue, ligament, tendon repair, wound care, or pain management, provided that these products meet stringent standards for retrieval, manufacture, and storage. The bill mandates that physicians must inform patients about the nature of the treatment, associated risks, and the fact that the products used have not been FDA-approved. Violations of these regulations could lead to disciplinary actions or criminal penalties, including felony charges for serious infractions. The Board of Podiatric Medicine is also granted the authority to adopt necessary rules for implementation.

Statutes affected:
S 1092 Filed: 461.007
S 1092 c2: 461.007
S 1092 er: 461.007